ChromaDex (CDXC) rebrands as Niagen Bioscience (NAGE) Mar 13, 2025 08:34AM
ChromaDex (CDXC) PT Raised to $11 at H.C. Wainwright Mar 10, 2025 06:44AM
ChromaDex (CDXC) Tops Q4 EPS by 7c Mar 4, 2025 04:03PM
ChromaDex (CDXC) Spike Over 7% as Traders Circulate Comments from Roth/MKM, 'unwarranted price weakness as a buying opportunity' Dec 6, 2024 08:53AM
ChromaDex (CDXC) Pharmaceutical-Grade Niagen IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide Nov 7, 2024 08:34AM


Nov 4, 2024 06:46AM ChromaDex (CDXC) PT Raised to $8 at H.C. Wainwright
Oct 31, 2024 04:04PM ChromaDex (CDXC) Tops Q3 EPS by 1c
Sep 20, 2024 08:32AM ChromaDex (CDXC) Appoints Ozan Pamir as Chief Financial Officer
Sep 10, 2024 08:33AM ChromaDex (CDXC) Announces Expansion of Pharmaceutical-Grade Niagen IV and Injection Offerings to Additional Leading Wellness Clinics
Aug 7, 2024 04:45PM ChromaDex (CDXC) Tops Q2 EPS by 2c
Jul 23, 2024 08:32AM ChromaDex (CDXC) Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners
Jul 15, 2024 08:29AM H.C. Wainwright Reiterates Buy Rating on ChromaDex (CDXC)